The US Food and Drug Administration (FDA) has approved the use of diagnostics provider Hologic's new C-View 2D imaging software.
C-View 2D images can now be used in place of the conventional 2D exposure previously required as part of a Hologic 3D mammography screening exam.
Studies have shown that screening with Hologic’s 3D mammography technology using C-View imaging provides better clinical results than that of a conventional 2D mammogram.
Hologic Breast Health senior vice president and general manager Peter Soltani said that the approval of C-View software is an important evolution in the company’s 3D mammography screening program.
"C-View software was developed to provide yet another option to imaging centers to improve patient care and clinical outcomes," Soltani added.